In a separate study, NSCLC patients receiving anti-EGFR treatment showed a median 19.19% change in the pre-treatment and on-treatment sPD-L1 level; though, there was no differences in the treatment response or progression free survival between patients with or without a reduction of sPD-L1 levels (211). This evidence concerns the gene EGFR and non-small cell lung carcinoma.